Therefore, the dependence on HSP90 has promoted the anti-leukemia drug development by depleting the molecular chaperone and degrading oncogenic Bcr-Abl, therefore eliciting apoptosis of leukemia cells [24–26]. The gene discussed is HSP90AA1; the disease is leukemia.